|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H19 |
Gene summary for H19 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H19 | Gene ID | 283120 |
| Gene name | H19 imprinted maternally expressed transcript | |
| Gene Alias | ASM | |
| Cytomap | 11p15.5 | |
| Gene Type | ncRNA | GO ID | GO:0000302 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 283120 | H19 | LZE2D | Human | Esophagus | HGIN | 5.68e-15 | 2.80e+00 | 0.0642 |
| 283120 | H19 | LZE2T | Human | Esophagus | ESCC | 1.80e-11 | 1.16e+00 | 0.082 |
| 283120 | H19 | LZE8T | Human | Esophagus | ESCC | 9.77e-06 | 5.77e-01 | 0.067 |
| 283120 | H19 | LZE22D1 | Human | Esophagus | HGIN | 1.88e-18 | 9.45e-01 | 0.0595 |
| 283120 | H19 | LZE22T | Human | Esophagus | ESCC | 6.43e-20 | 1.91e+00 | 0.068 |
| 283120 | H19 | LZE24T | Human | Esophagus | ESCC | 7.41e-13 | 8.11e-01 | 0.0596 |
| 283120 | H19 | S41 | Human | Liver | Cirrhotic | 2.57e-02 | 3.84e-01 | -0.0343 |
| 283120 | H19 | S42 | Human | Liver | HCC | 1.82e-02 | 6.56e-01 | -0.0103 |
| 283120 | H19 | S43 | Human | Liver | Cirrhotic | 1.60e-14 | 7.05e-01 | -0.0187 |
| 283120 | H19 | HCC1 | Human | Liver | HCC | 3.29e-07 | 3.70e+00 | 0.5336 |
| 283120 | H19 | HCC2 | Human | Liver | HCC | 2.13e-19 | 5.03e+00 | 0.5341 |
| 283120 | H19 | RNA-P17T-P17T-2 | Human | Lung | IAC | 2.13e-03 | 8.29e-01 | 0.3371 |
| 283120 | H19 | RNA-P17T-P17T-6 | Human | Lung | IAC | 4.71e-02 | 8.38e-01 | 0.3385 |
| 283120 | H19 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.44e-06 | 1.01e+00 | 0.3329 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000914212 | Liver | HCC | nucleoside triphosphate biosynthetic process | 57/7958 | 85/18723 | 4.10e-06 | 5.27e-05 | 57 |
| GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
| GO:00091995 | Liver | HCC | ribonucleoside triphosphate metabolic process | 58/7958 | 89/18723 | 1.31e-05 | 1.45e-04 | 58 |
| GO:000914412 | Liver | HCC | purine nucleoside triphosphate metabolic process | 57/7958 | 88/18723 | 2.03e-05 | 2.17e-04 | 57 |
| GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
| GO:003105021 | Liver | HCC | dsRNA processing | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:007091821 | Liver | HCC | production of small RNA involved in gene silencing by RNA | 38/7958 | 54/18723 | 3.15e-05 | 3.21e-04 | 38 |
| GO:00092015 | Liver | HCC | ribonucleoside triphosphate biosynthetic process | 49/7958 | 74/18723 | 3.21e-05 | 3.26e-04 | 49 |
| GO:200037722 | Liver | HCC | regulation of reactive oxygen species metabolic process | 92/7958 | 157/18723 | 3.34e-05 | 3.35e-04 | 92 |
| GO:190357822 | Liver | HCC | regulation of ATP metabolic process | 55/7958 | 87/18723 | 7.67e-05 | 6.85e-04 | 55 |
| GO:199074812 | Liver | HCC | cellular detoxification | 70/7958 | 116/18723 | 7.87e-05 | 7.02e-04 | 70 |
| GO:009723712 | Liver | HCC | cellular response to toxic substance | 74/7958 | 124/18723 | 8.36e-05 | 7.36e-04 | 74 |
| GO:003519621 | Liver | HCC | production of miRNAs involved in gene silencing by miRNA | 36/7958 | 52/18723 | 8.79e-05 | 7.66e-04 | 36 |
| GO:000920512 | Liver | HCC | purine ribonucleoside triphosphate metabolic process | 52/7958 | 82/18723 | 1.06e-04 | 9.08e-04 | 52 |
| GO:000616412 | Liver | HCC | purine nucleotide biosynthetic process | 107/7958 | 191/18723 | 1.08e-04 | 9.22e-04 | 107 |
| GO:000914512 | Liver | HCC | purine nucleoside triphosphate biosynthetic process | 45/7958 | 69/18723 | 1.16e-04 | 9.80e-04 | 45 |
| GO:009875412 | Liver | HCC | detoxification | 87/7958 | 152/18723 | 1.70e-04 | 1.35e-03 | 87 |
| GO:000920612 | Liver | HCC | purine ribonucleoside triphosphate biosynthetic process | 44/7958 | 68/18723 | 1.80e-04 | 1.41e-03 | 44 |
| GO:200037912 | Liver | HCC | positive regulation of reactive oxygen species metabolic process | 47/7958 | 76/18723 | 5.19e-04 | 3.38e-03 | 47 |
| GO:00067545 | Liver | HCC | ATP biosynthetic process | 37/7958 | 57/18723 | 5.28e-04 | 3.42e-03 | 37 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 283120 | H19 | CLINICALLY ACTIONABLE | Platinum compounds | 26729200 | ||
| 283120 | H19 | CLINICALLY ACTIONABLE | HORMONES | 8785513 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |